Fortress Biotech Stock News

MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializi

Generated record net product revenues of $63.1 million for the full year 2021

Company to hold conference call on March 23, 2022 at 4:30 p.m. ET Company to hold conference call on March 23, 2022 at 4:30 p.m. ET

MIAMI, March 09, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022.

MIAMI, March 09, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializi

MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializi

SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and

MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or mone

MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or moneti

In last trading session, Fortress Biotech Inc. (NASDAQ:FBIO) saw 0.34 million shares changing hands with its beta currently measuring 2.27. Company’s recent per share price level of $1.91 trading at -$0.01 or -0.52% at ring of the bell on the day assigns it a market valuation of $192.28M. That closing price of FBIO’s stock is … Fortress Biotech Inc. (NASDAQ:FBIO) Stock Dropped -23.60% Year-To-Date, What Analysts Expect Next? Read More »

MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or moneti

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will ring the closing bell at the Nasdaq MarketSite in Times Square today, Tuesday, December 21, 2021 at 4:00 p.m. EST. Fortress is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market.

Analysts predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will announce $29.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Fortress Biotechs earnings, with the lowest sales estimate coming in at $15.15 million and the highest estimate coming in at $75.52 million. Fortress Biotech reported sales of []

Generated record net revenues of $19.6 million for the third quarter of 2021

UBS Group reiterated their positive rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Tuesday, The Fly reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on FBIO. HC Wainwright reaffirmed a buy rating and set a […]